| Summary: | 碩士 === 國立嘉義大學 === 微生物免疫與生物藥學系研究所 === 102 === In recent years, changing in living and eating habits makes people get colon cancer and have a higher and higher proportion. Although colon cancer has close to 90% of the five-year survival rates, but it also has high metastasis rates, and makes colon cancer to be the fourth in the cancer death worldwide. Epirubicin, an anthracycline, is used to treat lymphoma, leukemia, and colon cancer. In normal conditions, moderate oxidative stress in the cells regulates physiological mechanism. Elevates intracellular oxidative stress over-production or low levels may make cell apoptosis. Propyl gallate is a synthetic compound, may have antioxidant ability to remove free radical. In the previous study, propyl gallate combined with epirubicin to treat colon cancer cell line, and found that propyl gallate could enhance epirubicin-mediated apoptosis. In this study, using antioxidants combines with epirubicin treatment, enhances the effect of antitumor ability. Co-treatment with epirubicin and antioxidants propyl gallate or ascorbic acid can decrease cell viability ratio in colon cancer cell line DLD-1 and HT-29. Incombination with epirubicin and gallic acid, N-acetylcystenine or glutathione increases cell cycle subG1 ratio in DLD-1, and incombination with epirubicin and ascorbic acid, N-acetylcystenine or glutathione increases cell cycle subG1 ratio in HT-29. Co-treatment with epirubicin and N-acetylcystenine increases intracellular ROS levels in DLD-1 and HT-29, but co-treatment with ascorbic acid decreases intracellular ROS levels in HT-29.
|
|---|
